IBM and University of Alberta publish new data on machine learning algorithms to help predict schizophrenia

Amii’s Russ Greiner is part of a team of researchers from the University of Alberta and IBM who are using machine learning to help predict schizophrenia.

Pioneering research in “computational psychiatry” uses AI to explore disease prediction and assessment

IBM (NYSE: IBM) scientists and the University of Alberta in Edmonton, Canada, have published new data in Nature‘s partner journal, Schizophrenia, demonstrating that AI and machine learning algorithms helped predict instances of schizophrenia with 74% accuracy. This retrospective analysis also showed the technology predicted the severity of specific symptoms in schizophrenia patients with significant correlation, based on correlations between activity observed across different regions of the brain. This pioneering research could also help scientists identify more reliable objective neuroimaging biomarkers that could be used to predict schizophrenia and its severity.

Schizophrenia is a chronic and debilitating neurological disorder that affects 7 or 8 out of every 1,000 people. Those with schizophrenia can experience hallucinations, delusions or thought disorders, along with cognitive impairments, such as an inability to pay attention and physical impairments, such as movement disorders.

“This unique, innovative multidisciplinary approach opens new insights and advances our understanding of the neurobiology of schizophrenia, which may help to improve the treatment and management of the disease,” says Dr. Serdar Dursun, a Professor of Psychiatry & Neuroscience with the University of Alberta. “We’ve discovered a number of significant abnormal connections in the brain that can be explored in future studies, and AI-created models bring us one step closer to finding objective neuroimaging-based patterns that are diagnostic and prognostic markers of schizophrenia.”

In the paper, researchers analyzed de-identified brain functional Magnetic Resonance Imaging (fMRI) data from the open data set, Function Biomedical Informatics Research Network (fBIRN) for patients with schizophrenia and schizoaffective disorders, as well as a healthy control group. fMRI measures brain activity through blood flow changes in particular areas of the brain. Specifically, the fBIRN data set reflects research done on brain networks at different levels of resolution, from data gathered while study participants conducted a common auditory test. Examining scans from 95 participants, researchers used machine learning techniques to develop a model of schizophrenia that identifies the connections in the brain most associated with the illness.

Regions of the brain that showed a statistically significant difference between patients with schizophrenia and patients without it. (Arrow 1 identifies the precentral gyrus, or the motor cortex, and arrow 5 marks the precuneus, which involves processing visual information.)

The results of the IBM and University of Alberta research demonstrated that, even on more challenging neuroimaging data collected from multiple sites (different machines, across different groups of subjects etc.) the machine learning algorithm was able to discriminate between patients with schizophrenia and the control group with 74% accuracy using the correlations in activity across different areas of the brain.

Additionally, the research showed that functional network connectivity could also help determine the severity of several symptoms after they have manifested in the patient, including inattentiveness, bizarre behavior and formal thought disorder, as well as alogia, (poverty of speech) and lack of motivation. The prediction of symptom severity could lead to a more quantitative, measurement-based characterization of schizophrenia; viewing the disease on a spectrum, as opposed to a binary label of diagnosis or non-diagnosis. This objective, data-driven approach to severity analysis could eventually help clinicians identify treatment plans that are customized to the individual.

“The ultimate goal of this research effort is to identify and develop objective, data-driven measures for characterizing mental states, and apply them to psychiatric and neurological disorders” said Ajay Royyuru, Vice President of Healthcare & Life Sciences, IBM Research. “We also hope to offer new insights into how AI and machine learning can be used to analyze psychiatric and neurological disorders to aid psychiatrists in their assessment and treatment of patients.”

The Research Domain Criteria (RDoC) initiative of NIMH emphasizes the importance of objective measurements in psychiatry. This field, often referred to as “computational psychiatry”, aims to use modern technology and data driven approaches to improve evidence-based medical decision making in psychiatry, a field that often relies upon subjective evaluation approaches.

As part of the ongoing partnership, researchers will continue to investigate areas and connections in the brain that hold significant links to schizophrenia. Work will continue on improving the algorithms by conducting machine learning analysis on larger datasets, and by exploring ways to extend these techniques to other psychiatric disorders such as depression or post-traumatic stress disorder.